ArticleMetabolites2021
Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics.
Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Urinary and cellular volatile organic compounds as biomarkers for urological cancers: a systematic review of GC-MS-based volatolomics.Metabolomics : Official journal of the Metabolomic Society · 2026Pooled it
- Multi-Omics Analysis of Primary Prostate Cancer Datasets Reveals Novel Biomarkers.Biochemical genetics · 2025Pooled it
- Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Article
- Metabolomic profiling in IgA nephropathy: urinary and salivary biomarker insights.BMC nephrology · 2026Article
- Urinary Volatilomic Signatures for Non-Invasive Detection of Lung Cancer: A HS-SPME/GC-MS Proof-of-Concept Study.International journal of molecular sciences · 2026Article
- Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics.The oncologist · 2026Review
- Volatile Organic Metabolites as Potential Biomarkers for Genitourinary Cancers: Review of the Applications and Detection Methods.Metabolites · 2025Review
- Insight into Fructose-to-Sucrose Ratio as the Potential Target of Urinalysis in Bladder Cancer.Metabolites · 2024Article
- Metabolomics for the diagnosis of bladder cancer: A systematic review.Asian journal of urology · 2024Review
- Urinary cancer detection by the target urine volatile organic compounds biosensor platform.Scientific reports · 2024Article
- Potential urinary volatile organic compounds as screening markers in cancer - a review.Frontiers in oncology · 2024Review
- Multiomic Approaches for Cancer Biomarker Discovery in Liquid Biopsies: Advances and Challenges.Biomarker insights · 2023Review
- Metabolomic and elemental profiling of blood serum in bladder cancer.Journal of pharmaceutical analysis · 2022Article
- Analysis of VOCs in Urine Samples Directed towards of Bladder Cancer Detection.Molecules (Basel, Switzerland) · 2022Article
- Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.International journal of molecular sciences · 2022Review
- A rapid LC-MS/MS assay for detection and monitoring of underivatized branched-chain amino acids in maple syrup urine disease.Journal of mass spectrometry and advances in the clinical lab · 2022Article
- Machine Learning in Prediction of Bladder Cancer on Clinical Laboratory Data.Diagnostics (Basel, Switzerland) · 2022Article
- Bladder cancer biomarker screening based on non-targeted urine metabolomics.International urology and nephrology · 2022Article
- A Panel of Bile Volatile Organic Compounds Servers as a Potential Diagnostic Biomarker for Gallbladder Cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Timely diagnosis is crucial to improve the long-term survival of bladder cancer (BC) patients. The discovery of new BC biomarkers based in urine analysis is very attractive because this biofluid is in direct contact with the inner bladder layer, in which most of the neoplasms develop, and is non-invasively collected. Hence, this work aimed to unveil alterations in the urinary volatile profile of patients diagnosed with BC compared with cancer-free individuals, as well as differences among patients diagnosed at different tumor stages, to identify candidate biomarkers for non-invasive BC diagnosis and staging. Urine analysis was performed by headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry (HS-SPME-GC-MS). The results unveiled that BC patients have a distinct urinary volatile profile characterized by higher levels of several alkanes and aromatic compounds, and lower levels of aldehydes, ketones and monoterpenes. Seventeen significantly altered volatiles were used to evaluate the performance for overall BC detection, disclosing 70% sensitivity, 89% specificity and 80% accuracy. Moreover, distinct urinary volatile profiles were found among patients diagnosed at different tumor stages (Ta/Tis, T1 and ≥T2). This work identified distinct urinary volatile signatures of BC patients with potential for non-invasive detection and staging of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.